

Author index to Volume 4

- Aapro M. Delivering the benefits of anti-emetic innovation (Introduction), 353*
- Aapro M. A framework for assessing therapeutic innovation, 2753
- Ackermann M *et al.* Low dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon- α and/or interleukin-2 based antineoplastic therapy, 585
- Adamo DO. *See* Bicher A, 141
- Adomat H. *See* Matthews JB, 463
- Aggarwal SK & Fadool JM. Cisplatin and carboplatin induced changes in the neurohypophysis and parathyroid, and their role in nephrotoxicity, 149
- Ainsworth S. *See* Helson L, 487
- Alama A. *See* Ryte A, 197
- Albuquerque J. *See* Manso Ribiero M, 2352
- Alessandro N. *See* Borsellino N, 265
- Alvizatos G & Oosterhof GON. Update of hormonal treatment in cancer of the prostate, 301
- Allegra CJ. *See* Drake JC, 431; *also* Grem JL, 454
- Alouf JE. *See* Jolivet-Reynaud C, 65
- Andrade J. *See* Manso Ribiero M, 2352
- Andreoli F. *See* Neri B, 323
- Angioni A. *See* Donfrancesco A, 317
- Ankanthil R. *See* Sreelekha TT, 209
- Arndt D. *See* Zeisig R, 57
- Asada M. *See* Ashizawa T, 577
- Ashizawa T *et al.* Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice, 577
- Ashizawa T *et al.* Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice, 181
- Assaraf YG. Characterization by flow cytometry and fluorescein-methotrexate labeling of hydrophilic and lipophilic antifolate resistance in cultured mammalian cells, 535
- Assaraf YG & Borgnia MJ. Differential reversal of lipophilic antifolate resistance in mammalian cells with modulators of the multidrug resistance phenotype, 395
- Atzpodien J. *See* Ackermann M, 585
- Augusti-Tocco G. *See* Carpinelli P, 629
- Aulenbacher P. *See* Gietema JA, 51
- Baccarani M. *See* Damiani D, 173
- Balis FM. *See* Rodriguez G, 163
- Baltali E. *See* Özyilkan, 98
- Bartolucci S. *See* Carpinelli P, 629
- Batarda M. *See* Manso Ribiero M, 2352
- Beaufils H. *See* Martinez F, 85
- Behrens DL. *See* Chen SF, 447
- Ben-Dor CG. *See* Isacson R, 189
- Benhmida M. *See* Martinez F, 85
- Bennett C. *See* Gulati S, 1351
- Berdowska I. *See* Mikulewicz W, 341
- Bibby MC & Double JA. Flavone acetic acid—from laboratory to clinic and back, 3
- Bicher A *et al.* The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor, 141
- Blijham GH. Prevention and treatment of organ toxicity during high-dose chemotherapy: an overview, 527
- Boesch D. *See* Jachez B, 223, 593
- Boglino C. *See* Donfrancesco A, 317
- Borgnia MJ. *See* Assaraf YG, 395
- Borrelli D. *See* Neri B, 323
- Borsellino N *et al.* Antiproliferative and chemomodulatory effects of interferon- γ on doxorubicin-sensitive and resistant tumor cell lines, 265
- Borsellino N. *See* Gebbia V, 443
- Bosanquet N. The costs of healthcare: implications for anti-emetic therapy, 953
- Bourbouze R. *See* Martinez F, 85
- Brandão A. *See* Manso Ribiero M, 2352
- Breillout F. *See* Zhou X-J, 511
- Bronchud M. Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy? 127
- Brown TD *et al.* Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study, 49
- Brown TD. *See* Rodriguez G, 163
- Brufman G. *See* Isacson R, 189
- Bruno S. *See* Neri B, 323
- Bruno T. *See* Castiglione S, 407
- Brunsgaard N. *See* Kjaer M, 437
- Burke TG. *See* Priebe W, 37
- Burris III HA. *See* Rinaldi DA, 33
- Cannata G. *See* Gebbia V, 443
- Canti GF. *See* Ryte A, 197
- Cañete M. *See* Juarranz A, 501
- Carpinelli P *et al.* Antiproliferative effects and DNA hypomethylation by 5-aza-2'-deoxycytidine in human neuroblastoma cell lines, 629
- Carreca I. *See* Gebbia V, 443
- Castiglione S *et al.* Rhein inhibits glucose uptake in Ehrlich ascites tumor cells by alteration of membrane-associated functions, 407
- Castro I. *See* Manso Ribiero M, 2352
- Cerno M. *See* Damiani D, 173
- Chan LC. *See* Liang R, 339
- Chan TK. *See* Liang R, 339
- Chedid L. *See* Jolivet-Reynaud C, 65
- Chen LK. *See* Hall IH, 389
- Chen SF *et al.* XB596, a promising bis-naphthalimide anti-cancer agent, 447
- Chersi A. *See* Castiglione S, 407
- Chi LK. *See* Hall IH, 665
- Chiba I. *See* Shibata T, 657
- Chiu E. *See* Liang R, 339
- Chiu M-C. *See* Liaw C-C, 311
- Chou C. *See* Rinaldi DA, 33
- Chow WS. *See* Liang R, 339
- Christensen C. *See* Saunders DE, 201
- Christian M. *See* Bicher A, 141
- Cipolla C. *See* Gebbia V, 443
- Clark GM. *See* El-Zayat AAE, 19
- Côté S & Momparler RL. Evaluation of the antineoplastic activity of Adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells, 327
- Cozza R. *See* Donfrancesco A, 317
- Craig JB. *See* Brown TD, 49; *also* Rodriguez G, 163
- Crescimanno M. *See* Borsellino N, 265
- Curto G. *See* Gebbia V, 443
- Czerniak PM. *See* Chen SF, 447
- Damiani D *et al.* D-Verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin, 173
- Daoud SS & Sakata MK. *In vitro* interaction of liposomal valinomycin and platinum analogs: cytotoxic and cytokinetic effects, 479

* S denotes reference to pages in a supplement.

- Davis P. *See* Bicher A, 141
 de Castro T. *See* Manso Ribiero M, 2352
 de Carvalho V. *See* Manso Ribiero M, 2352
 de Faria L. *See* Manso Ribiero M, 2352
 de Greef GE. *See* Löwenberg B, 1751
 de Matos E. *See* Manso Ribiero M, 2352
 de Oliveira E. *See* Manso Ribiero M, 2352
 de Vries EGE. *See* Gietema JA, 51
 Deb G. *See* Donfrancesco A, 317
 Degen D. *See* El-Zayat AAE, 19
 Del Carlo C. *See* Castiglione S, 407
 Denham CA. *See* Rodriguez G, 163
 Deppe G. *See* Saunders DE, 201
 Deray G. *See* Martinez F, 85
 Dev PK. *See* Gupta RR, 589
 Devinsky F. *See* Miko M, 355, 471
 Dexter TM & Fairbairn LJ. The molecular control of hematopoiesis, 551
 Dexter DL. *See* Chen SF, 447
 Diaz V. *See* Juarranz A, 501
 Donfrancesco A *et al.* D-CECaT: a breakthrough for patients with neuroblastoma, 317
 Dong QG *et al.* Isolation of a mitomycin-resistant human lung adenocarcinoma cell sultine to investigate the modulation by sodium butyrate of cell growth and drug resistance, 617
 dos Reis F. *See* Manso Ribiero M, 2352
 Double JA. *See* Bibby MC, 3
 Drabek S. *See* El-Zayat AAE, 19
 Drake JC *et al.* Immunological quantitation of thymidylate synthase-FdUMP-5, 10-methylentetrahydrofolate ternary complex with the monoclonal antibody TS 106, 431
 Drake JC. *See* Grem JL, 545
 Drzewiecki G. *See* Kandaswami C, 91
 Dubois M. *See* Martinez F, 85
 Dusak BL. *See* Chen SF, 447
 Edwards CL. *See* Kudelka AP, 335
 Edwards DMF. *See* Kjaer M, 437
 Einstein AB. *See* Brown TD, 49
 Ekman A. *See* Hand A, 365
 El-Zayat AAE *et al.* *In vitro* evaluation of the antineoplastic activity of combretastatin A-4, a natural product from *Combretum caffrum* (arid shrub), 19
 Engelhard M. First experiences and perspectives for the use of cytokines in the treatment of non-Hodgkin's lymphoma, 2151
 Erlichman C. *See* Moore MJ, 555
 Estrada J. *See* Jolivet-Reynaud C, 65
 Evangelista M. *See* Castiglione S, 407
 Fabbri S. *See* Neri B, 323
 Fadool JM. *See* Aggarwal SK, 149
 Fairbairn LJ. *See* Dexter TM, 551
 Fanciulli M. *See* Castiglione S, 407
 Fichtinger-Schepman AMJ. *See* Shellard SA, 491
 Fine S. *See* Moore MJ, 555
 Firat D. *See* Özyilkan, 98
 Flandina C. *See* Borsellino N, 265
 Fleming T. *See* Brown TD, 49
 Floch L. *See* Horáková K, 369
 Florena M. *See* Gebbia V, 443
 Floridi A. *See* Castiglione S, 407
 Focan C *et al.* Ambulatory treatment with 5 days continuous venous infusion of ifosfamide for advanced colorectal cancer: a phase II feasibility study, 459
 Fráguas A. *See* Manso Ribiero M, 2352
 Franco P. *See* Ryte A, 197
 Fredericks JR. *See* Chen SF, 447
 Freeman AJ. The vomiting reflex and the role of 5-HT₁ receptors, 952
 Freedman RS. *See* Kudelka AP, 335
 Frim O. *See* Stanojevic-Bakic N, 565
 Gadner H. *See* Zoubek A, 1752
 Gale KC. *See* Chen SF, 447
 Garça Moura P. *See* Manso Ribiero M, 2352
 Gebbia N. *See* Gebbia V, 443
 Gebbia V *et al.* Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy, 443
 Gemelli MT. *See* Neri B, 323
 Gerson R. *See* Montero R, 351
 Gietema JA *et al.* A phase I study of lobaplatin (D-19466) administered by 72h continuous infusion, 51
 Gil N. *See* Manso Ribiero M, 2352
 Gomi K. *See* Ashizawa T, 181, 577
 Gong LL. *See* Dong QG, 617
 Gonshebb M-E. *See* Montero R, 351; *also* Rojas E, 637
 Goodman PJ. *See* Brown TD, 49
 Gopal A. *See* Gulati S, 1351
 Gopal R. *See* Gulati S, 1351
 Granata F. *See* Carpinelli P, 629
 Grasberger MA. *See* Jachez B, 223, 593
 Grem JL *et al.* Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography, 545
 Gross JL. *See* Chen SF, 447
 Guchelaar H-J. *See* Gietema JA, 51
 Gulati S *et al.* Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease, 1351
 Güler N. *See* Özyilkan, 98
 Gupta A. *See* Gupta RR, 589
 Gupta RR *et al.* Anticancer activities of 2,3-dihydro-1,4-benzothiazines, and their 4-(N-alkylamides) and 4-(N-alkyl-N-nitrosoamides), 589
 Hagiwara A *et al.* Selective delivery of etoposide to intraperitoneal tissues using a new dosage format: etoposide microcrystals suspended in oil, 27
 Hagiwara A. *See* Tsujimoto H, 377; *also* Sakakura C, 381
 Hall ES. *See* Hall IH, 389
 Hall IH *et al.* The cytotoxicity of heterocyclic thiosemicarbazones and their metal complexes on human and murine tissue culture cells, 231
 Hall IH *et al.* The cytotoxicity of N-substituted indazolones in murine and human tumor cells, 389
 Hall IH *et al.* The cytotoxicity of N-substituted diphenimides and 6,7-dihydro-5H-dibenz[c,e]azepines, 665
 Hall IG. *See* West DX, 241
 Halme M. *See* Hand A, 365
 Hand A *et al.* Interferon- α and interferon- γ combined with chemotherapy: *in vitro* sensitivity studies in non-small cell lung cancer cell lines, 365
 Hasegawa T *et al.* Isothiocyanates inhibit cell cycle progression of HeLa cells at G₂/M phase, 273
 Havlin K. *See* Rodriguez G, 163
 Helson C. *See* Helson L, 487
 Helson L *et al.* A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells, 487
 Helson L. *See* Donfrancesco A, 317
 Hénichart JP. *See* Mestdagh N, 641
 Herrera L-A. *See* Montero R, 351; *also* Rojas E, 637
 Hill BT. *See* Shellard SA, 491
 Hirata T. *See* Ashizawa T, 181, 577
 Hong WK. *See* Rinaldi DA, 33
 Horáková K *et al.* Ethyl 4-isothiocyanatobutanoate—antiproliferative activity *in vitro* and *in vivo*, 369
 Horta L. *See* Manso Ribiero M, 2352
 Hoshi A. *See* Maeda M, 167
 Hosokawa M. *See* Shibata T, 657
 Huang J-S. *See* Liaw C-C, 311
 Hurst T. *See* Kearsley JH, 571
 Husgafvel-Pursiainen K. *See* Hand A, 365
 Ilson DH & Kelson DP. Chemotherapy in esophageal cancer, 287
 Inock A. *See* Manso Ribiero M, 2352
 Isacson R *et al.* A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluoro-uracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes, 189
 Iwashima A. *See* Hasegawa T, 273

- Jachez B & Loor F. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents, 605
- Jachez B *et al.* Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives, 223
- Jachez B *et al.* Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives, 593
- Jacob J. *See* Bicher A, 141
- Jacobs C. *See* Martinez F, 85
- Jacquiaud C. *See* Martinez F, 85
- Jakobsen P. *See* Kjaer M, 437
- Jantová S. *See* Horáková K, 369
- Jarmulowicz J. *See* Mikulewicz W, 341
- Jaudon M-C. *See* Martinez F, 85
- Jenkner A. *See* Donfrancesco A, 317
- Jiang JB. *See* Chen SF, 447
- Johnston PG. *See* Drake JC, 431
- Jolivet-Reynaud C *et al.* Targeting of GM2-bearing tumor cells with the cytolytic *Clostridium perfringens* delta toxin, 65
- Juarranz A *et al.* Induced photolysis of rabbit red blood cells by several photosensitizers, 501
- Jungmann S. *See* Zeisig R, 57
- Justiça B. *See* Manso Ribiero M, 2352
- Kaizer L. *See* Moore MJ, 555
- Kandaswami C *et al.* Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma *in vitro*, 91
- Kars A. *See* Özyilkan, 98
- Kasahara N. *See* Sakamoto S, 651
- Kavanagh JJ. *See* Kudelka AP, 335
- Kearsley JH & Thomas S. Prognostic markers in cancer of the head and neck region, 419
- Kearsley JH *et al.* Chemosensitivity testing of primary cultures of Merkel cell cancer, 571
- Kelson DP. *See* Ilson DH, 287
- Kerr DJ. *See* Zoumpourlis V, 77
- Khoo SK. *See* Kearsley JH, 571
- Kido Y *et al.* Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines, 251
- Khokhar AR. *See* Kido Y, 251
- Kirchner H. *See* Ackermann M, 585
- Kirchner V. Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs, 1353
- Kirshenbaum MR. *See* Chen SF, 447
- Kjaer M *et al.* Bioavailability of a new oral formulation of medroxyprogesterone acetate compared with the standard formulation: a single dose randomized study, 437
- Kobayashi E. *See* Ashizawa T, 577
- Kobayashi H. *See* Shibata T, 657
- Kohn E. *See* Bicher A, 141
- Krakoff IH. *See* Kudelka AP, 335
- Kreutz F. *See* Focan C, 459
- Kronberger M. *See* Zoubek A, 1752
- Kudelka AP *et al.* Metastatic adenocarcinoma of the endometrium treated with 13-*cis*-retinoic acid plus interferon- α , 335
- Kudo H. *See* Sakamoto S, 651
- Kuhn JG. *See* Rodriguez G, 163
- Kwong YL. *See* Liang R, 339
- Landi H. *See* Zhou X-J, 511
- Landolfo A. *See* Donfrancesco A, 317
- Latteri MA. *See* Gebbia V, 443
- Lawrence WD. *See* Saunders DE, 201
- Lazo JS. *See* Shellard SA, 491
- Lee M. *See* Hagiwara A, 27
- Leonardi V. *See* Borsellino N, 265
- Leone V. *See* Neri B, 323
- Levi F. *See* Focan C, 459
- Liang R *et al.* Effective salvage therapy using all-*trans* retinoic acid for relapsed and resistant acute promyelocytic leukemia, 339
- Liaw C-C *et al.* Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil, 311
- Liaw S-J. *See* Liaw C-C, 311
- Liberta AE. *See* West DX, 231; *also* Hall IH, 231
- Lie A. *See* Liang R, 339
- Linnainmaa K. *See* Hand A, 365
- Lippman SM. *See* Rinaldi DA, 33; *also* Kudelka AP, 335
- Loor F. *See* Jachez B, 223, 593, 605
- Löwenberg B *et al.* Granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of hematological malignancies, 1751
- Macdonald JS. *See* Brown TD, 49
- Maeda M *et al.* Antitumor activity of a new series of platinum complexes: *trans*($\pm$)-1,2-cyclohexanediammine-platinum(II) conjugated to acid polysaccharides, 167
- Maity P. *See* Pal S, 505
- Malik S. *See* Helson L, 487
- Malone JM. *See* Saunders DE, 201
- Malviya VK. *See* Saunders DE, 201
- Mangiardi J. *See* Helson L, 487
- Manso Ribiero M *et al.* (Portuguese Ondansetron Study Group). Ondansetron in the treatment of nausea and vomiting induced by chemotherapy, 2352
- Martinez F *et al.* Comparative nephrotoxicity of carboplatin and cisplatin in euvoletic and dehydrated rats, 85
- Matthews JB *et al.* The effect of hypoxia on cytotoxicity, accumulation and DNA binding of cisplatin in Chinese hamster ovary cells, 463
- Mattson K. *See* Hand A, 365
- Mattson M. *See* Hand A, 365
- Maurizio C. *See* Donfrancesco A, 317
- Mazzei M. *See* Ryte A, 197
- McRipley RJ. *See* Chen SF, 447
- Melli C. *See* Damiani D, 173
- Mendes Ribeiro M. *See* Manso Ribiero M, 2352
- Mestdagh N *et al.* Effect of various chemosensitizers on chemoresistance to adriamycin in MIP-101 cell line, a colon carcinoma cell line: analysis of glutathione and related enzymes, 641
- Morier-Teissier E. *See* Mestdagh N, 641
- Micallef M. Immunoregulatory cytokine production by tumor-bearing rats spleen cells and its modulation by bleomycin, 213
- Micallef M. *See* Shibata T, 657
- Michelutti A. *See* Damiani D, 173
- Michieli M. *See* Damiani D, 173
- Middleton Jr E. *See* Kandaswami C, 91
- Miko M & Devinsky F. *In vitro* cytotoxic activity of 1-alkylpiperidine *N*-oxides and quantitative structure-activity relationships, 355
- Miko M & Devinsky F. Effect of membrane active 1-alkylpiperidine *N*-oxides on glycolysis, respiration and ATP level in tumor cells, 471
- Mikulewicz W *et al.* Decrease *in vivo* of cysteine endopeptidases in blood of patients with tumor of the larynx, 341
- Mizuno M. *See* Sakamoto S, 651
- Momparler RL. *See* Côté S, 327
- Montero R *et al.* AS-101: a modulator of *in vitro* T-cell proliferation, 351
- Montero R. *See* Rojas E, 637
- Moore MJ *et al.* A phase II study of 5-fluorouracil, leucovorin and interferon- α in advanced pancreatic cancer, 555
- Morelli S. *See* Ryte A, 197
- Mori T. *See* Sakamoto S, 651
- Mulder NH. *See* Gietema JA, 51
- Muranishi S. *See* Hagiwara A, 27
- Nagasawa H. *See* Sakamoto S, 651
- Nagase S. *See* Watanabe S, 345
- Nair MK. *See* Sreelekha TT, 209

- Neri B *et al.* Epidoxorubicin and high dose leucovorin plus 5-fluorouracil in advanced gastric cancer: a phase II study, 323
- Nicolin A. *See* Ryte A, 197
- Nishino H. *See* Hasegawa T, 273
- Nissen E. *See* Zeisig R, 57
- Novotná L. *See* Horáková K, 369
- Nyati M. *See* Gupta RR, 589
- Ohyama T. *See* Tsujimoto H, 377
- Okabe M. *See* Ashizawa T, 181, 577
- Okano S. *See* Sakakura C, 381
- Oosterhof GON. *See* Alivizatos G, 301
- Osaki K. *See* Tsujimoto H, 377
- Ostrosky-Wegman P. *See* Montero R, 351; also Rojas E, 637
- Ozaki K. *See* Sakakura C, 381
- Özyilkan Ö *et al.* Intrapleural and intraperitoneal palliative treatment of malignant effusions with mitoxantrone, 98
- Paggi MG. *See* Castiglione S, 407
- Pal S *et al.* Tumor inhibition and hematopoietic stimulation in mice by a synthetic copper-ATP complex, 505
- Pantalone D. *See* Neri B, 323
- Papp LM. *See* Chen SF, 447
- Patten AD. *See* Chen SF, 447
- Pelin K. *See* Hand A, 365
- Perez-Soler R. *See* Priebe W, 37
- Perkins E. *See* Kandaswami C, 91
- Perrella FW. *See* Chen SF, 447
- Pettit GR. *See* El-Zayat AAE, 19
- Pinguinha A. *See* Manso Ribiero M, 2352
- Pinto Ribeiro A. *See* Manso Ribiero M, 2352
- Portuguese Odansetron Study Group. *See* Manso Ribiero M, 2352
- Priebe W *et al.* Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity, 37
- Puschmann A. *See* Zoubeck A, 1752
- Rahmani R. *See* Zhou X-J, 511
- Rajendran KG. *See* Hall IH, 231
- Rajner L. *See* Stanojevic-Bakic N, 565
- Rajoria CM. *See* Gupta RR, 589
- Rausa L. *See* Borsellino N, 265
- Ray MR. *See* Pal S, 505
- Reed E. *See* Bicher A, 141
- Rees GJG. Assessing the benefits of anti-emetic innovation, 553
- Rejendran KG. *See* West DX, 241
- Ribeiro I. *See* Manso Ribiero M, 2352
- Ribeiro M. *See* Manso Ribiero M, 2352
- Rinaldi DA *et al.* Phase II study of 13-*cis*-retinoic acid and interferon- α 2a in patients with advanced squamous cell lung cancer, 33
- Rodriguez G *et al.* A phase I trial of trimetrexate (NSC352122) on a daily $\times$ 5 schedule in patients with refractory adult leukemia, 163
- Rodríguez R. *See* Rojas E, 637
- Rodríguez-Borlado L. *See* Juarranz A, 501
- Rojas E *et al.* Mitotic index and cell proliferation kinetics for identification of antineoplastic activity, 637
- Rojas E. *See* Montero R, 351
- Rossi M. *See* Carpinelli P, 629
- Ryte A *et al.* Oligonucleotide degradation contributes to resistance to antisense compounds, 197
- Safra T. *See* Isacson R, 189
- Saito T. *See* Watanabe S, 345
- Sakakibara T. *See* Tsujimoto H, 377
- Sakakura C *et al.* Enhancement of LAK-like activity and cytokine induction in regional lymph nodes and spleen cells of mice after intralymphnodal injection of OK-432, a killed streptococcal preparation, 381
- Sakakura C. *See* Hagiwara A, 27; also Tsujimoto H, 377
- Sakamoto S *et al.* Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice, 651
- Sakata MK. *See* Daoud SS, 479
- Sarosy G. *See* Bicher A, 141
- Sasaki S. *See* Tsujimoto H, 377; also Sakakura C, 381
- Sato S. *See* Watanabe S, 345
- Saunders DE *et al.* Inhibition of *c-myc* in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D $_3$, retinoic acid and dexamethasone, 201
- Sawai S. *See* Sakakura C, 381
- Scarffe JH. Future outlook for growth factors, 2751
- Schultz JF. *See* Saunders DE, 201
- Schütt A. *See* Zeisig R, 57
- Seitz SP. *See* Chen SF, 447
- Shafik A. Intratunical injection of methotrexate for the treatment of seminoma of the testicle, 193
- Sharma ML. *See* Gupta RR, 589
- Shellard SA *et al.* Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines, 491
- Shibata T *et al.* Modulation of the shedding of a rat tumor-associated antigen by growth regulation and anti-cancer drugs, 657
- Shoubayashi S. *See* Hagiwara A, 27
- Siddik ZH. *See* Kido Y, 251
- Siewinski M. Autologous cysteine peptidase inhibitors as potential anti-cancer drugs, 97
- Siewinski M. *See* Mikulewicz W, 341
- Sjöholm Å. Sodium butyrate inhibits rat insulinoma cell proliferation without affecting the cellular insulin content or insulin release, 259
- Sleijfer DTh. *See* Gietema JA, 51
- Soloniuk DS. *See* Kandaswami C, 91
- Sordo M. *See* Rojas E, 637
- Sousa e Silva A. *See* Manso Ribiero M, 2352
- Spandidos DA. *See* Zoumpourlis V, 77
- Spuzic I. *See* Stanojevic-Bakic N, 565
- Sreelekha TT *et al.* Immunomodulatory effects of a polysaccharide from *Tamarindus indica*, 209
- Stafford MP. *See* Chen SF, 447
- Stanojevic-Bakic N *et al.* Enhancement of phytohemagglutinin-induced lymphoproliferative response by indomethacin, Thymex L or their combination in lung cancer patients, 565
- Steele RJC. *See* Watson SA, 599
- Skov KA. *See* Matthews JB, 463
- Stred'ansky M. *See* Horáková K, 369
- Strolin-Benedetti M. *See* Kjaer M, 437
- Suga T. *See* Maeda M, 167
- Sugiura Y. *See* Sakamoto S, 651
- Sun JH. *See* Chen SF, 447
- Sun T. *See* Chen SF, 447
- Suzuki S. *See* Sakamoto S, 651
- Takahashi T. *See* Hagiwara A, 27; also Sakakura C, 381; also Tsujimoto H, 377
- Takasuka N. *See* Maeda M, 167
- Tashima S. *See* Hagiwara A, 27
- Teixeira C. *See* Manso Ribiero M, 2352
- Tekuzman G. *See* Özyilkan, 98
- Teresa Rodrigues M. *See* Manso Ribiero M, 2352
- Thomas S. *See* Kearsley JH, 419
- Testa A. *See* Gebbia V, 443
- Tisdale MJ. Cancer cachexia, 115
- Toia M. *See* Gulati S, 1351
- Tornos CS. *See* Kudelka AP, 335
- Trigueros C. *See* Juarranz A, 501
- Tsujimoto H *et al.* Cisplatin microcrystals suspended in oil—toxicity in mice, 377
- Tsujimoto H. *See* Sakakura C, 381
- Uehara N. *See* Maeda M, 167
- Uva S. *See* Manso Ribiero M, 2352
- Uziely B. *See* Isacson R, 189
- Valenza R. *See* Gebbia V, 443
- Valeri A. *See* Neri B, 323
- Vallas M. *See* Hand A, 365
- Van NT. *See* Priebe W, 37
- Vijayakumar T. *See* Sreelekha TT, 209

Author index to Volume 4

- Vijayan KK. *See* Sreelekha TT, 209
 Villanueva A. *See* Juarranz A, 501
 Von Hoff DD. *See* Chen SF, 447; *also*
 El-Zayat AAE, 19; *also* Rinaldi DA, 33;
 also Rodriguez G, 163
 Vuckovic-Dekic L. *See* Stanojevic-Bakic,
 565

 Wang C-H. *See* Liaw C-C, 311
 Wang HJ. *See* Dong QG, 617
 Wang EZ. *See* Dong QG, 617
 Wappler NL. *See* Saunders DE, 201
 Watanabe S *et al.* Polyamine increase in
 rat tissues treated with 1- β -D-
 arabinosylcystosine and 5-fluorouracil,
 345

 Watson SA & Steele RJC. Gastrin
 antagonists in the treatment of gastric
 cancer, 599
 West DX *et al.* The cytotoxicity of
 copper(II) complexes of heterocyclic
 thiosemicarbazones and 2-substituted
 pyridine N-oxides, 241
 West DX. *See* Hall IH, 231
 West LA. *See* Jolivet-Reynaud C, 65
 Wielenga JJ. *See* Löwenberg B, 1751
 Wong OT. *See* Hall IH, 389, 665
 Wuonola MA. *See* Chen SF, 447

 Yamamoto A. *See* Hagiwara A, 27
 Yamane T. *See* Sakakura C, 381

 Zammit-Lucia J. Modeling budgetary
 impact for decision makers, 2153
 Zeisig R *et al.* Antineoplastic activity *in*
 vitro of free and liposomal alkyl-
 phosphocholines, 57
 Zhou X-J *et al.* Pharmacokinetics of
 navelbine after oral administration in
 the dog and the monkey, 511
 Zoubek A *et al.* Ondansetron in the control
 of chemotherapy-induced and
 radiotherapy-induced emesis in
 children with malignancies, 1752
 Zoumpourlis V *et al.* Differential
 interaction of cisplatin with the HIV-1
 long terminal repeat in a resistant
 ovarian carcinoma cell line, 77

Key word index to Volume 4

- Acid polysaccharides
conjugated, 167
- Acute
emesis, 21S3*
lymphoblastic leukemia,
209
myeloid leukemia, 17S1
promyelocytic leukaemia,
339
- Adenocarcinoma, 335
- Adozelesin, 327
- Adriamycin, 641
- Advanced
gastric cancer, 323
malignancy, 585
- Alkylphospholipid, 57
- 1-Alkylpiperidine *N*-oxides,
355, 471
- 4-(*N*-alkyl amides), 589
- 4-(*N*-alkyl *N*-nitrosamides),
589
- All-*trans* retinoic acid, 339
- Amonafide, 49
- Anthracycline, 173
- antibiotics, 37
- Anti-cancer
activity, 637
drugs, 223
drug efflux, 605
emetic drugs, 9S3
emetics, 13S3
neoplastics, 665
tumor activity, 3
tumor agents, 447
- Antifolate resistance, 535
- Antigen shedding, 657
- Antileukemic, 231
- Antineoplastic, 231
activity, 57
- Antiproliferative effects, 265
- Antisense
oligodeoxynucleotides,
197
- Antitoxidant, 91
- Antitumor, 181
activity, 167
agents, 589
drugs, 657
- 1- β -D-Arabinosylcytosine,
345
- Arid shrub, 19
- AS-101, 351
- Ascorbic acid, 91
- Aspartate
carbamoyltransferase, 545
- ATP, 471
- Atypical multi-drug
resistance, 605
- Autocrine growth, 17S1
- Autologous bone marrow
transplantation, 13S1
- 5-aza-2'-deoxycytidine, 327,
629
- Azepine purine inhibitors,
665
- Biochemical monitoring, 545
- Biological response
modifiers, 381
- Biology, 419
- Bis-naphthalimide
compounds, 447
- Breast cancer, 437
- Budget, 21S3
- Cachexia, 115, 585
- Cancer, 91, 115, 287
- Carboplatin, 77, 85, 149
- Cardiotoxicity, 37
- Cell
cultures, 571
cycle kinetics, 17S1
proliferation, 629
kinetics, 351, 637
- Cellular uptake, 197
- Chemoresistance, 641
- Chemosensitivity, 571
- Chemotherapy, 115, 173,
287, 311, 323, 327, 365,
527, 17S1, 23S2
and radiotherapy-induced
nausea and emesis, 9S2,
17S2
related diarrhea, 443
induced vomiting, 13S3
- Children, 17S2
- CHO cells, 463
- Cisplatin, 77, 85, 149, 377,
463, 577, 617
DNA adducts, 491
- 13-*cis*-retinoic acid, 335
- Clinical, 559
- Clostridium perfringens*, 65
- Co, 231
- Colon carcinoma, 327
- Colorectal cancer, 49, 459
- Combination, 577
chemotherapy, 189
- Combretastatin A-4, 19
- Combretum caffrum*, 19
- Continuous
infusion, 51
venous infusion, 459
- Copper complexes, 241
- Cost, 21S3
analysis, 9S3, 13S3
benefit, 9S3
effectiveness, 9S3, 13S3
- Cu, 231
- Cu-ATP complex, 505
- Cumulative toxicity, 141
- Cystatins, 341
- Cytokine
arabinoside, 327
induction, 381
- Cytotoxic synergism, 479
- Cytotoxicity, 355, 389
- D-19466, 51
- D-CECaT, 317
- Delayed emesis, 21S3
- Delta toxin, 65
- Dexamethasone, 5S3
- Dihydrofolate reductase, 395
- 2,3-dihydro-1,4
benzothiazines, 589
- Diphenimides, 665
- DNA, 447
binding, 463
methylation, 629
platinum binding, 251
repair, 491
synthesis inhibitors, 665
synthesizing enzyme, 651
- Dose, 163
dependency, 511
intensity, 141
- Doxorubicin, 37
- Drug
accumulation, 463
distribution, 27
delivery system, 27, 167
resistance, 617
uptake, 251
- Ehrlich cells, 355
and L1210 cells, 471
- Eicosanylphosphocholine,
57
- Endometrium, 335
- Epidoxorubicin, 323
- Esophageal, 287
- Etherlipid, 57
- Ethyl 4-isothiocyanato
butanoate, 369
- ETOP-OIL, 27
- Etoposide, 27
- Fibrosarcoma, 657
- Flavone acetic acid, 3
- Flavonoids, 91
- Flow cytometry, 479, 535
- 5-fluorouracil, 311, 323, 345,
431, 459, 555, 651
- G-CSF, 127
- G₂/M phase arrest, 273
- Gastric cancer, 599
- Gastrin, 599
- Glioblastoma multiforme,
487
- Glucose transport, 407
- Glutathione, 641
- Glycolysis, 471
- GM-CSF, 127
- GM2, 65
- Granisetron, 527, 553
- Granulocyte
colony stimulating factor,
5S1
macrophage colony
stimulating factor, 5S1,
13S1, 17S1, 21S1, 27S1
- Growth
inhibition, 617
inhibitory cytokines, 27S1
inhibitory effect, 273
- Head and neck cancer, 419
- Hematopoietic
growth factors, 127
stimulation, 505
- Hemopoietic
stem cells, 5S1
support, 27S1
- Hepatotoxicity, 163

* S denotes reference to pages in a supplement.

Key word index to Volume 4

- Hexadecylphosphocholine, 57
HGF, 127
High-dose chemotherapy, 13S1, 27S1, 127
HIV-1, 77
Hodgkin's disease, 13S1
Hormonal treatment, 301
HPLC, 545
5-HT₃ receptors, 9S2
 antagonists, 21S3
 receptor antagonists, 5S3
Human
 lymphocytes, 3S1, 637
 lung adenocarcinoma, 617
 lung carcinoma cell lines, 491
 neuroblastoma, 629
Hydroxyrubicin, 37
Hypoxic, 463

Ifosfamide, 459
IMP dehydrogenase, 231, 241, 389
In vitro and *in vivo*
 interaction, 369
In-hospital charges, 13S1
Indazolones, 389
Indomethacin, 565
Insulin, 259
Insulinoma, 259
Interferon, 33, 5S5, 365
 α , 17S1, 33S, 58S
 β , 26S
Interleukin
 1, 381
 2, 21S1, 58S
 3, 17S1, 21S1
Interphase death, 369
Intralymphnodal injection, 381
Intraperitoneal
 administration, 27
 chemotherapy, 377
Isomers, 251
Isothiocyanate, 273

KW-2149, 181

L1210 leukemia, 241
LAK-like cells, 381
Leucovorin, 323, 5S5, 5S9
Leukemia, 163
Leukocyte migration
 inhibition, 209
Lipophilic antifolates, 39S
Liposomal valinomycin, 479
Liposomes, 57
Lobaplatin, 51
Loperamide, 443
Lung
 cancer, 33, 56S
 carcinoma, 327
Lymphoroliferative
 response, 56S

Macrophage inflammatory
 protein-1 α , 5S1
Mechanisms, 3
Megestrol acetate, 58S
Membrane(s), 407, 501
Merkel cell carcinoma, 571
Metal complexes, 231
Metallothionein content, 491
Methotrexate, 193, 53S
Metoclopramide, 5S3
Mice, 50S
MIP-101, 641
Mitomycin C, 181, 617
Mitotic index, 637
Mitoxantrone, 189
Mode of action, 3S5
Modulators, 39S
Monoclonal antibody, 431
Mouse, 181
 mammary tumor, 6S1
MPA bioavailability, 437
MTT assay, 487
Multidrug resistance (MDR), 37, 223, 26S, 39S
Myeloid cell recovery, 13S1
Myelosuppression, 527

N-(phosphonancetyl)-1
 aspartate, 54S
Nausea, 5S3, 23S2, 527
Navelbine, 511, 577
Nephrotoxicity, 8S, 149
Neuroblastoma, 317, 487
Neurohypophysis, 149
Ni, 231
Non-cisplatin, 23S2
Non-Hodgkin's lymphoma, 21S1
Non-small cell lung cancer, 36S
Nucleic acid inhibitors, 389

Octadecylphosphocholine, 57
Octreotide, 443
Oil suspension, 377
OK-432, 381
Ondansetron, 5S3, 9S2, 17S2, 23S2
Oral administration, 511
Organ toxicity, 527
Osteosarcoma, 5S9
Ovarian cancer, 141
 carcinoma, 479

P-glycoprotein, 223, 39S, 60S
Pancreatic cancer, 5S5
Parathyroid, 149
Pediatric cancer patients, 17S2
Peripheral blood stem cell
 rescue, 27S1
Phagocytosis, 209
Pharmacokinetics, 437, 511
Phase I study, 51, 163
Phase II
 study, 323
 trial, 49
Photohemolysis, 501
Photosensitizers, 501
Platelet recovery, 13S1
Platinum analogs, 479
Polyamine, 34S
Polysaccharide, 209
Predictive assay, 571
Primitive neuroectodermal
 tumor, 317, 487
Prognostic factors, 419
Proliferation, 91
Prostate cancer, 301
Protein kinase C, 479
Pt(II) complexes, 167
Purine
 inhibitors, 231, 389
 synthesis inhibitors, 241
Putrescine, 34S

QSAR, 3S5
Quercetin, 91

Rat, 8S
Receptor antagonists, 599
Resistance, 173
 modulating agents, 223, 60S
Resistant cells, 197

Respiration, 471
Retinoic acid, 33
Reversion, 641
Rhein, 407
RINm5F cells, 2S9

Seminoma, 193
Serotonin receptor
 antagonists, 13S3
SHN virgin mouse, 6S1
Singlet oxygen, 501
Sodium butyrate, 2S9, 617
Spermidine, 34S
Spermine, 34S
Squamous cell, 33
 cancer, 419
Stability, 197
Stage II breast cancer, 189
Stromal cells, 5S1

Tamarindus indica, 209
Taxol, 141, 487
Testicle, 193
Testicular tumors, 193
Tetraplatin, 2S1
Therapy, 341
Thiol groups, 471
Thiosemicarbazones, 231, 241
Thymex L, 56S
Thymidylate synthase, 431
Toxicity, 181, 377
Transforming growth factor
 β , 5S1
Transient
 hyperammonemia, 311
Trimetaxate, 163
Tumor, 11S
 cells, 407
 cell growth, 6S7
 inhibition, 50S
 necrosis factor, 381

Unbalanced
 cell metabolism, 369
 growth, 369
Urine, 341

Vasopressin, 149
Vomiting, 5S3, 9S2, 23S2, 527

Wistar King rat, 6S7
XB596, 447